Cardiome Pharma (CRME) Tops Q3 EPS by 1c

Cardiome Pharma (NASDAQ: CRME) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $5.68 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Greenlane Holdings Inc. (GNLN) reported Q2 result
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c